Schraa et al., 2022 - Google Patents
Cell-free circulating (tumor) DNA before surgery as a prognostic factor in non-metastatic colorectal cancer: a systematic reviewSchraa et al., 2022
View HTML- Document ID
- 17258229007781022264
- Author
- Schraa S
- van Rooijen K
- Koopman M
- Vink G
- Fijneman R
- Publication year
- Publication venue
- Cancers
External Links
Snippet
Simple Summary Patients with colorectal cancer without distant metastases are often cured by surgical tumor resection. Follow-up is needed because of the risk of disease recurrence. Patients at risk of disease recurrence may benefit from additional chemotherapy. Detection …
- 201000011231 colorectal cancer 0 title abstract description 76
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
- C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
- C12Q1/6886—Hybridisation probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06Q—DATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q50/00—Systems or methods specially adapted for a specific business sector, e.g. utilities or tourism
- G06Q50/10—Services
- G06Q50/22—Health care, e.g. hospitals; Social work
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06Q—DATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q50/00—Systems or methods specially adapted for a specific business sector, e.g. utilities or tourism
- G06Q50/01—Social networking
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
- G06F19/10—Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Moody et al. | The efficacy of miR-20a as a diagnostic and prognostic biomarker for colorectal cancer: a systematic review and meta-analysis | |
Schraa et al. | Cell-free circulating (tumor) DNA before surgery as a prognostic factor in non-metastatic colorectal cancer: a systematic review | |
Shi et al. | Frequent gene amplification predicts poor prognosis in gastric cancer | |
Nakamura et al. | Circulating microRNA panel as a potential novel biomarker for oral squamous cell carcinoma diagnosis | |
Swets et al. | Tumor LINE-1 methylation level in association with survival of patients with stage II colon cancer | |
Tonella et al. | Prognostic and predictive biomarkers in stage III melanoma: Current insights and clinical implications | |
Abudukadeer et al. | Clinical relevance of CDH1 and CDH13 DNA-methylation in serum of cervical cancer patients | |
Thiele et al. | lncRNAs in non-malignant tissue have prognostic value in colorectal cancer | |
Batista et al. | TERT promoter mutation as a potential predictive biomarker in BCG-treated bladder cancer patients | |
Carrasco et al. | Cell-free DNA as a prognostic biomarker for monitoring muscle-invasive bladder cancer | |
Adam-Artigues et al. | Identification of a two-microRNA signature in plasma as a novel biomarker for very early diagnosis of breast cancer | |
Park et al. | MicroRNA profile for diagnostic and prognostic biomarkers in thyroid cancer | |
Harsanyi et al. | Biomarkers of bladder cancer: cell-free DNA, epigenetic modifications and non-coding RNAs | |
Sequeira et al. | LiKidMiRs: A ddPCR-based panel of 4 circulating miRNAs for detection of renal cell carcinoma | |
Tsiakanikas et al. | High expression of a tRNAPro derivative associates with poor survival and independently predicts colorectal cancer recurrence | |
Souza et al. | Liquid biopsy in lung cancer: biomarkers for the management of recurrence and metastasis | |
Nørgaard et al. | Comprehensive evaluation of TFF3 promoter hypomethylation and molecular biomarker potential for prostate cancer diagnosis and prognosis | |
Wang et al. | Automatic detection of the circulating cell-free methylated DNA pattern of GCM2, ITPRIPL1 and CCDC181 for detection of early breast cancer and surgical treatment response | |
Ntzifa et al. | DNA methylation analysis in plasma cell-free DNA and paired CTCs of NSCLC patients before and after osimertinib treatment | |
Chang et al. | Associations of timp-3 genetic polymorphisms with egfr statuses and cancer clinicopathologic development in lung adenocarcinoma patients | |
Hsieh et al. | Impact of matrix metalloproteinase-11 gene polymorphisms on biochemical recurrence and clinicopathological characteristics of prostate cancer | |
Kunac et al. | Activation of cGAS-STING Pathway Is associated with MSI-H Stage IV colorectal cancer | |
Dudea-Simon et al. | Alteration of gene and miRNA expression in cervical intraepithelial neoplasia and cervical cancer | |
Lee et al. | Predictive value of circulating miRNAs in lymph node metastasis for colon cancer | |
Kottorou et al. | Differentially methylated ultra-conserved regions Uc160 and Uc283 in adenomas and adenocarcinomas are associated with overall survival of colorectal cancer patients |